We also noted that previous studies have shown the selective anti-tumor effects in RAF-mutated melanomas (46), which explains our observations that MEK1/2 inhibitor did not alter the apoptosis of B16F10 melanoma cells in vitro and animal survival in vivo. This evidence concerns the gene MAP2K1 and neoplasm.